BACKGROUND: Surgical correction of craniosynostosis in children is associated with substantial intraoperative bleeding. Tranexamic acid (TXA) decreases intraoperative blood loss during cardiac or orthopedic surgery in children. We hypothesized that intraoperative TXA would reduce blood transfusion relative to placebo in patients pretreated witherythropoietin. METHODS:Forty consecutive children, American Society of Anesthesiologists status 1 or 2, scheduled to undergo surgical correction of craniosynostosis were randomly assigned to receive either intravenous TXA or saline, 0.9%, intraoperatively. All children received preoperative erythropoietin (600 U/kg once a week for 3 weeks before surgery). Perioperative blood loss, number and volume of transfusions, percentage of children who underwent transfusion, and side effects were noted after surgery and at the end of the study. Surgeon satisfaction and cost of treatment were also recorded. RESULTS: There was no significant difference between groups in demographic or surgical data. In the TXA group, the volume of packed erythrocytes transfused was significantly reduced by 85% (from 11 to 1.6 ml/kg) intraoperatively and by 57% (from 16.6 to 7.2 ml/kg) throughout the study period (P < 0.05). Compared with the placebo group, the percentage of children requiring blood transfusion was lower in the TXA group during surgery (9 [45%] of 20 vs. 2 [11%] of 19 children; P < 0.05) and during the whole study period (14 [70%] of 20 vs. 7 [37%] of 19; P < 0.05). Preoperative and postoperative hematologic parameters were comparable in both groups. There were no adverse events. CONCLUSION: In children undergoing surgical correction of craniosynostosis and pretreated witherythropoietin, intraoperative TXA reduces the transfusion requirement.
RCT Entities:
BACKGROUND: Surgical correction of craniosynostosis in children is associated with substantial intraoperative bleeding. Tranexamic acid (TXA) decreases intraoperative blood loss during cardiac or orthopedic surgery in children. We hypothesized that intraoperative TXA would reduce blood transfusion relative to placebo in patients pretreated with erythropoietin. METHODS: Forty consecutive children, American Society of Anesthesiologists status 1 or 2, scheduled to undergo surgical correction of craniosynostosis were randomly assigned to receive either intravenous TXA or saline, 0.9%, intraoperatively. All children received preoperative erythropoietin (600 U/kg once a week for 3 weeks before surgery). Perioperative blood loss, number and volume of transfusions, percentage of children who underwent transfusion, and side effects were noted after surgery and at the end of the study. Surgeon satisfaction and cost of treatment were also recorded. RESULTS: There was no significant difference between groups in demographic or surgical data. In the TXA group, the volume of packed erythrocytes transfused was significantly reduced by 85% (from 11 to 1.6 ml/kg) intraoperatively and by 57% (from 16.6 to 7.2 ml/kg) throughout the study period (P < 0.05). Compared with the placebo group, the percentage of children requiring blood transfusion was lower in the TXA group during surgery (9 [45%] of 20 vs. 2 [11%] of 19 children; P < 0.05) and during the whole study period (14 [70%] of 20 vs. 7 [37%] of 19; P < 0.05). Preoperative and postoperative hematologic parameters were comparable in both groups. There were no adverse events. CONCLUSION: In children undergoing surgical correction of craniosynostosis and pretreated with erythropoietin, intraoperative TXA reduces the transfusion requirement.
Authors: José Luiz de Faria; Josué da Silva Brito; Louise Teixeira Costa E Silva; Christiano Tadeu Sanches Mattos Kilesse; Nicolli Bellotti de Souza; Carlos Umberto Pereira; Eberval Gadelha Figueiredo; Nícollas Nunes Rabelo Journal: Neurosurg Rev Date: 2020-06-17 Impact factor: 3.042
Authors: Paul J Escher; Albert Tu; Susan Kearney; Matthew Wheelwright; Joseph Petronio; Meysam Kebriaei; Sivakumar Chinnadurai; Robert J Tibesar Journal: Childs Nerv Syst Date: 2019-05-30 Impact factor: 1.475
Authors: Christopher M Bonfield; Julia Sharma; D Douglas Cochrane; Ash Singhal; Paul Steinbok Journal: Childs Nerv Syst Date: 2015-09-08 Impact factor: 1.475
Authors: Susan M Goobie; Petra M Meier; Navil F Sethna; Sulpicio G Soriano; David Zurakowski; Snehal Samant; Luis M Pereira Journal: Clin Pharmacokinet Date: 2013-04 Impact factor: 6.447
Authors: P A Stricker; A F Zuppa; J E Fiadjoe; L G Maxwell; E M Sussman; E Y Pruitt; T K Goebel; M R Gastonguay; J A Taylor; S P Bartlett; M S Schreiner Journal: Br J Anaesth Date: 2013-01-25 Impact factor: 9.166
Authors: Thanh T Nguyen; Sarah Hill; Thomas M Austin; Gina M Whitney; John C Wellons; Humphrey V Lam Journal: J Neurosurg Pediatr Date: 2015-07-31 Impact factor: 2.375